Evidence map›Paper›PMID 31970877›Full record

ArticleJournal of cellular and molecular medicine2020

Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF

Hao Fu, Lin Cheng, Ri Sa, Yuchen Jin, Libo Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cellular and molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hao FuDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Lin ChengDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Ri SaDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Yuchen JinDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Libo ChenDepartment of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.ORCID 0000-0002-2822-9785
Shanghai Jiao Tong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical efficacy of differentiation therapy with mitogen-activated protein kinase inhibitors (MAPKi) for lethal radioiodine-refractory papillary thyroid cancer (RR-PTC) urgently needs to be improved and the aberrant trimethylation of histone H3 lysine 27 (H3K27) plays a vital role in BRAF

Indexed as

BenzamidesBenzimidazolesBiphenyl CompoundsCell DifferentiationCell Line, TumorDrug Resistance, NeoplasmEnhancer of Zeste Homolog 2 ProteinGene Expression Regulation, NeoplasticHistonesHumansImidazolesIodine RadioisotopesMethylationMitogen-Activated Protein KinasesMorpholinesOximesAZD 6244BenzamidesBenzimidazolesBiphenyl CompoundsBRAF protein, humandabrafenibEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanHistonesImidazolesIodine RadioisotopesMitogen-Activated Protein KinasesMorpholinesOximesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafPyridonestazemetostatdifferentiation therapyEZH2 inhibitorH3K27me3MAPK inhibitorthyroid cancer

Identifiers

PMID31970877
PMCPMC7131946
OpenAlexW3002315770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.